Crestor shines for Shionogi as antibiotics flag
This article was originally published in Scrip
Helped by the contribution of the acquired Sciele business in the US, Shionogi has reported an 8% rise in its total sales, to ¥143.4 billion ($1.78 billion), in the first half ended 30 September.
You may also be interested in...
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.